Evidence map›Paper›PMID 35019721›Full record

ArticleJournal of virology2022

Host T Cell Dedifferentiation Effects Drive HIV-1 Latency Stability.

Alexander G Dalecki, Braxton D Greer, Alexandra Duverger, Elan L Strange, Eric Carlin, Frederic Wagner, Bi Shi, Kelsey E Lowman, Mildred Perez, Christopher Tidwell and 6 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Alexander G Dalecki *Department of Medicine, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Braxton D Greer *Department of Medicine, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Alexandra DuvergerDepartment of Medicine, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Elan L StrangeDepartment of Medicine, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Eric CarlinDepartment of Medicine, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Frederic WagnerDepartment of Medicine, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Bi ShiDepartment of Microbiology, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Kelsey E LowmanDepartment of Medicine, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Mildred PerezDepartment of Medicine, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Christopher TidwellDepartment of Medicine, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Katarzyna Kaczmarek MichaelsDepartment of Medicine and Microbiology, Boston University School of Medicine, Boston, Massachusetts, USA.
Sophia GiattinaDepartment of Medicine, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Stefan H BossmannThe University of Kansas Medical Center, Department of Cancer Biology, Kansas City, Kansas, USA.
Andrew J HendersonDepartment of Medicine and Microbiology, Boston University School of Medicine, Boston, Massachusetts, USA.
Hui HuDepartment of Microbiology, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.
Olaf KutschDepartment of Medicine, The University of Alabama at Birminghamgrid.265892.2, Birmingham, Alabama, USA.ORCID 0000-0002-1853-8023
University of Alabama at Birmingham · USBoston University · USThe University of Kansas Cancer Center · US

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Overcoming HIV-1 transcriptional latency in unresponsive CD4 T cellsR01AI122842 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KUTSCH, OLAF · 2017 to 2020
$2.6M
Signals that establish and maintain HIV latencyR01AI138960 · NIAID · BOSTON MEDICAL CENTER · PI HENDERSON, ANDREW J · 2018 to 2022
$2.2M
Transcriptional regulation of T cell quiescience and activationR01AI095439 · NIAID · WISTAR INSTITUTE · PI HU, HUI · 2012 to 2016
$1.9M
Effect of opioid use disorder on HIV latent reservoirs and immune dysfunction assessed by single-cell transcriptomicsR33DA047032 · NIDA · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI CHENG, CHRISTINE, HENDERSON, ANDREW J · 2021 to 2022
$1.8M
Identification of drugs that induce terminal transcriptional silencing of latent HIV-1 infectionR33AI133679 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KUTSCH, OLAF · 2020 to 2021
$1.4M
Kinomic analysis of host cell factors controlling latent HIV-1 infectionR33AI116188 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KUTSCH, OLAF · 2016 to 2018
$1.3M
Negative regulatory pathways in T cell quiescence and T cell responseR01AI103162 · NIAID · WISTAR INSTITUTE · PI HU, HUI · 2012 to 2016
$1.2M
NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI042853NIAID NIH HHS R01 AI095439NIAID NIH HHS R01 AI103162NIAID NIH HHS R01 AI122842NIAID NIH HHS R01 AI138960NIAID NIH HHS R33 AI116188NIAID NIH HHS R33 AI133679NIDA NIH HHS R33 DA047032
6 · The paper itself

Abstract

The development of therapies to eliminate the latent HIV-1 reservoir is hampered by our incomplete understanding of the biomolecular mechanism governing HIV-1 latency. To further complicate matters, recent single-cell RNA sequencing (scRNA-seq) studies reported extensive heterogeneity between latently HIV-1-infected primary T cells, implying that latent HIV-1 infection can persist in greatly differing host cell environments. We show here that transcriptomic heterogeneity is also found between latently infected T cell lines, which allowed us to study the underlying mechanisms of intercell heterogeneity at high signal resolution. Latently infected T cells exhibited a dedifferentiated phenotype, characterized by the loss of T cell-specific markers and gene regulation profiles reminiscent of hematopoietic stem cells (HSC). These changes had functional consequences. As reported for stem cells, latently HIV-1-infected T cells efficiently forced lentiviral superinfections into a latent state and favored glycolysis. As a result, metabolic reprogramming or cell redifferentiation destabilized latent infection. Guided by these findings, data mining of single-cell RNA-seq data of latently HIV-1-infected primary T cells from patients revealed the presence of similar dedifferentiation motifs. More than 20% of the highly detectable genes that were differentially regulated in latently infected cells were associated with hematopoietic lineage development (e.g., HUWE1, IRF4, PRDM1, BATF3, TOX, ID2, IKZF3, and CDK6) or were hematopoietic markers (SRGN; hematopoietic proteoglycan core protein). The data add to evidence that the biomolecular phenotype of latently HIV-1-infected cells differs from that of normal T cells and strategies to address their differential phenotype need to be considered in the design of therapeutic cure interventions.

Indexed as

CD4-Positive T-LymphocytesCell DedifferentiationHIV-1HIV InfectionsVirus LatencyHumansdedifferentiationhematopoietic stem cell phenotypeHIV-1host cell restrictionlatency

Identifiers

PMID35019721
PMCPMC8906408
OpenAlexW4205102474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.